MARKET

DCTH

DCTH

Delcath Sys
NASDAQ
12.22
-0.21
-1.69%
After Hours: 12.14 -0.08 -0.62% 19:59 07/24 EDT
OPEN
12.44
PREV CLOSE
12.43
HIGH
12.57
LOW
12.12
VOLUME
301.36K
TURNOVER
--
52 WEEK HIGH
13.74
52 WEEK LOW
8.12
MARKET CAP
421.85M
P/E (TTM)
2036.67
1D
5D
1M
3M
1Y
5Y
1D
Press Release: Delcath Systems to Host Second Quarter 2026 Earnings Call
Dow Jones · 1d ago
Delcath Systems schedules second-quarter 2026 earnings call
PUBT · 1d ago
Weekly Report: what happened at DCTH last week (0713-0717)?
Weekly Report · 4d ago
Delcath Systems grants 17,000 inducement RSUs to four new hires
PUBT · 07/16 20:01
DELCATH SYSTEMS, INC. ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 07/16 20:01
Delcath Systems price target raised to $17 from $16 at BTIG
TipRanks · 07/13 11:20
DELCATH SYSTEMS INC <DCTH.O>: BTIG RAISES TARGET PRICE TO $17 FROM $16
Reuters · 07/13 09:59
Weekly Report: what happened at DCTH last week (0706-0710)?
Weekly Report · 07/13 09:14
More
About DCTH
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Webull offers Delcath Systems Inc stock information, including NASDAQ: DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.